Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03935126 · ClinicalTrials.gov registry record
Global Atrophie Biomarker Evaluation Study (GABiE)
A clinical trial, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- 3
- Enrollment target
NCT03935126 is a clinical trial that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 3 participants.
The verdict
NCT03935126 was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
Interventions
- DIAGNOSTIC_TEST Diagnostics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-05-07 |
| Est. Completion | 2020-05-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03935126
The ClinicalTrials.gov registry entry for NCT03935126 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Diagnostics is the first listed.
NCT03935126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03935126 about?
NCT03935126 is a clinical study titled "Global Atrophie Biomarker Evaluation Study (GABiE)". To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
What is the current status of trial NCT03935126?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2019-05-07. Estimated completion is 2020-05-14.
What interventions are being tested in trial NCT03935126?
The interventions under investigation include: Diagnostics (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03935126?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.